Brief: Nurix Therapeutics Announces Bexobrutideg Oral Presentation
12/05/2026 22:06
May 12 (Reuters) - Nurix Therapeutics Inc NRIX.O: NURIX THERAPEUTICS ANNOUNCES BEXOBRUTIDEG ORAL PRESENTATION AT THE 2026 EUROPEAN HEMATOLOGY ASSOCIATION CONGRESS Source text: ID:nGNXbCY1NY Further company coverage: NRIX.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Nurix Therapeutics
See all newsNurix Therapeutics Q3 swings to profit on Roche collaboration
Brief: Nurix Extends Gilead Collaboration For Oncology Program
Commercialize Potential Best-In-Class Btk Degrader Bexobrutideg Across Malignant Hematology, Immunology And Neurology
Nurix Therapeutics Q2 revenue falls sharply, net loss widens; strikes up to $2.3 bln collab with Roche
U.S. RESEARCH ROUNDUP- Datadog, Jabil, Prologis